[Click eStock] "Samsung Biologics: Strike Impact to Be Reflected From Q3... Target Price Lowered"
On July 2, Shinhan Investment Corp. lowered its target price for Samsung Biologics from 1.9 million won to 1.8 million won, citing the expected impact of the strike to be reflected from the third quarter of this year. The investment opinion remains 'Buy'.
Lee Hocheol, a researcher at Shinhan Investment Corp., stated, "From a performance perspective, we have factored in the expected decrease in third-quarter revenue due to the strike and the anticipated increase in labor costs from 2027. On the valuation side, we applied a lower EV/EBITDA multiple compared to industry peers, reflecting reduced cash generation capability." He further explained, "With labor and management still at odds, there is potential for changes in second-half revenue guidance and mid- to long-term profitability depending on the details of the negotiations."
Samsung Biologics' second-quarter results for this year are expected to meet market expectations. Lee commented, "Second-quarter revenue is projected to be 1.32 trillion won, up 30.5% year-on-year, and operating profit is estimated at 607.1 billion won, up 27.3%, in line with consensus (the average of securities firms' forecasts). The production disruption caused by the strike in the first week of May, amounting to approximately 150 billion won, will be reflected in third-quarter revenue. The temporary decrease in production volume is expected to be offset by additional production starting from the fourth quarter."
Lee emphasized the importance of the outcome of the wage and collective bargaining agreement. "Even if an agreement is reached between labor and management, the mid- to long-term burden of increased labor costs is inevitable," he said. "If a one-time performance-based bonus amount is determined as a result of the negotiations, corresponding provisions will be reflected, and earnings estimates will be revised accordingly."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The company's mid- to long-term growth potential remains high. Lee noted, "The decision to commence construction on the sixth plant, which is expected to be finalized within this year, in itself serves as evidence of a strong order backlog. In June, competitor WuXi AppTec was listed on the U.S. Department of Defense's 1260H (Chinese military companies) list, raising the possibility that it may be designated as a biosecurity risk company under the Biosecurity Law. With the final list scheduled for confirmation within this year, Samsung Biologics is expected to benefit indirectly as U.S.-China tensions escalate."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.